Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110749 | 0.86 | MAOA (0.47) | KDM4CMAOAMAOBCYP19A1 | |
| SCHEMBL643762 | 0.84 | HAO1 (0.32) | KDM4CHAO1 | |
| SCHEMBL9523645 | 0.81 | CYP11B2 (0.38) | CYP3A4CYP11B2CYP19A1 | |
| SCHEMBL17361744 | 0.77 | KDM4C (0.36) | KDM4CMAOAMAOBHAO1MGLL | |
| Hydrochloric Acid SCHEMBL30558475 | 0.76 | KDM4C (0.36) | KDM4CMAOAMAOBHAO1MGLL | |
| SCHEMBL14775682 | 0.76 | KDM4C (0.44) | KDM4CHAO1MGLLPARP10PARP11 | |
| SCHEMBL641724 | 0.74 | KDM4C (0.39) | KDM4CHAO1MGLLPARP10PARP11 | |
| SCHEMBL769025 | 0.72 | PARP1 (0.40) | KDM4CCYP3A4CYP11B2PARP10CYP19A1 | |
| SCHEMBL643507 | 0.71 | MAOA (0.37) | MAOAMAOB | |
| SCHEMBL642086 | 0.70 | MAOA (0.54) | KDM4CMAOAMAOBPARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365494-B2 | Process for synthesis of amino-methyl tetralin derivatives | ROCHE PALO ALTO LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365494-B2 | Process for synthesis of amino-methyl tetralin derivatives | ROCHE PALO ALTO LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365494-B2 | Process for synthesis of amino-methyl tetralin derivatives | ROCHE PALO ALTO LLC (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2379491-B1 | Process for synthesis of amino-methyl tetraline derivatives | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| EP-2379491-B1 | Process for synthesis of amino-methyl tetraline derivatives | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | DURKIN KIERAN (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | DURKIN KIERAN (US) | 2012-12-20 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119842-B2 | Process for synthesis of amino-methyl tetralin derivatives | Roche Palo Alto LLP (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2379491-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069778-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160682-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | KDM4C 1363/4885MAOA 2897/4885MAOB 2165/4885 |
| US-20120323040-A1 | PROCESS FOR SYNTHESIS OF AMINO-METHYL TETRALIN DERIVATIVES | PKN2, CCND2, PRMT1 | KDM4C 1334/4885MAOA 2990/4885MAOB 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.